Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

A Topeka church and cemetery are getting some national recognition after being added to a federal list of places that have ...

We recently compiled a list of the 15 Stocks to Invest in with Steady Dividends. In this article, we are going to take a look ...

"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...

Kansas lawmakers are considering a bill this week which would use the Division of Vehicles (DOV) to inform officials about ...

The FDA approves Johnson & Johnson's sNDA for Spravato as a monotherapy for adults with treatment-resistant depression.

On the company’s Q4 earnings call where an eyepopping $88.8 billion in full-year sales were revealed, leaders shifted focus ...

The Trump administration’s first drug pricing action — rescinding a Biden executive order encouraging Medicare to help lower ...

Millions of us take vitamins, minerals, and other supplements daily to improve our health and well-being—but taking certain ...

Toward the end of Donald Trump’s inauguration speech, sandwiched between his promises to take back the Panama Canal from ...

The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...